Loading…

Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose

The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY(3-36) and GLP-1(7-36 amide), on glucose homeostasis are unknown. This study sought to investigate the acut...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2014-11, Vol.99 (11), p.E2317-E2324
Main Authors: Tan, Tricia M, Salem, Victoria, Troke, Rachel C, Alsafi, Ali, Field, Benjamin C T, De Silva, Akila, Misra, Shivani, Baynes, Kevin C R, Donaldson, Mandy, Minnion, James, Ghatei, Mohammad A, Godsland, Ian F, Bloom, Stephen R
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page E2324
container_issue 11
container_start_page E2317
container_title The journal of clinical endocrinology and metabolism
container_volume 99
creator Tan, Tricia M
Salem, Victoria
Troke, Rachel C
Alsafi, Ali
Field, Benjamin C T
De Silva, Akila
Misra, Shivani
Baynes, Kevin C R
Donaldson, Mandy
Minnion, James
Ghatei, Mohammad A
Godsland, Ian F
Bloom, Stephen R
description The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY(3-36) and GLP-1(7-36 amide), on glucose homeostasis are unknown. This study sought to investigate the acute effects of PYY(3-36) and GLP-1(7-36) amide, individually and in combination, on insulin secretion and sensitivity. Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY(3-36) alone, GLP-1(7-36) amide alone, and a combination of PYY(3-36) and GLP-1(7-36) amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. PYY(3-36) alone caused a small but nonsignificant increase in AIRg. GLP-1(7-36) amide alone and the combination of PYY(3-36) and GLP-1(7-36) amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. PYY(3-36) lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-1(7-36) amide alone and the combination of PYY3-36 and GLP-1(7-36) amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY(3-36) and GLP-1(7-36) amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.
doi_str_mv 10.1210/jc.2014-2143
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1622061137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1622061137</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-50694d786ce7afa3d21031dd108c4aacb6066d33114a9b1e366bf562300542d63</originalsourceid><addsrcrecordid>eNo1kM1LAzEQxYMgtlZvniXHekjNJNlse5SitVDQgwo9Ldlk1qbsl5tdpP-90dbTvDe_x4MZQm6Az0AAv9_bmeCgmAAlz8gYFiphKSzSEbkMYc8jUom8ICORRKWlGJPDsqlyX5veNzVtCtpi23uHdLuVTGr67fsdXW1eGUzT6O-oqX6pNUPAQE1NfW07NAGjoIXvQs_a3dGGoYy7gJH_lZuix46uP-hnOdgm4BU5L0wZ8Po0J-T96fFt-cw2L6v18mHDWlDQs4TrhXLpXFtMTWGki3dKcA743CpjbK651k5KAGUWOaDUOi8SLSTniRJOywmZHnvbrvkaMPRZ5YPFsjQ1NkPIQAvBNYBMY_T2FB3yCl3Wdr4y3SH7f5f8AfRAZ7k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1622061137</pqid></control><display><type>article</type><title>Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose</title><source>Oxford Journals Online</source><creator>Tan, Tricia M ; Salem, Victoria ; Troke, Rachel C ; Alsafi, Ali ; Field, Benjamin C T ; De Silva, Akila ; Misra, Shivani ; Baynes, Kevin C R ; Donaldson, Mandy ; Minnion, James ; Ghatei, Mohammad A ; Godsland, Ian F ; Bloom, Stephen R</creator><creatorcontrib>Tan, Tricia M ; Salem, Victoria ; Troke, Rachel C ; Alsafi, Ali ; Field, Benjamin C T ; De Silva, Akila ; Misra, Shivani ; Baynes, Kevin C R ; Donaldson, Mandy ; Minnion, James ; Ghatei, Mohammad A ; Godsland, Ian F ; Bloom, Stephen R</creatorcontrib><description>The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY(3-36) and GLP-1(7-36 amide), on glucose homeostasis are unknown. This study sought to investigate the acute effects of PYY(3-36) and GLP-1(7-36) amide, individually and in combination, on insulin secretion and sensitivity. Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY(3-36) alone, GLP-1(7-36) amide alone, and a combination of PYY(3-36) and GLP-1(7-36) amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. PYY(3-36) alone caused a small but nonsignificant increase in AIRg. GLP-1(7-36) amide alone and the combination of PYY(3-36) and GLP-1(7-36) amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. PYY(3-36) lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-1(7-36) amide alone and the combination of PYY3-36 and GLP-1(7-36) amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY(3-36) and GLP-1(7-36) amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.</description><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2014-2143</identifier><identifier>PMID: 25144632</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Blood Glucose ; Female ; Glucagon-Like Peptide 1 - pharmacology ; Glucose - administration &amp; dosage ; Glucose Tolerance Test ; Homeostasis - drug effects ; Humans ; Insulin - blood ; Insulin Resistance ; Male ; Middle Aged ; Obesity - blood ; Overweight - blood ; Peptide Fragments - pharmacology ; Peptide YY - pharmacology ; Young Adult</subject><ispartof>The journal of clinical endocrinology and metabolism, 2014-11, Vol.99 (11), p.E2317-E2324</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25144632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tan, Tricia M</creatorcontrib><creatorcontrib>Salem, Victoria</creatorcontrib><creatorcontrib>Troke, Rachel C</creatorcontrib><creatorcontrib>Alsafi, Ali</creatorcontrib><creatorcontrib>Field, Benjamin C T</creatorcontrib><creatorcontrib>De Silva, Akila</creatorcontrib><creatorcontrib>Misra, Shivani</creatorcontrib><creatorcontrib>Baynes, Kevin C R</creatorcontrib><creatorcontrib>Donaldson, Mandy</creatorcontrib><creatorcontrib>Minnion, James</creatorcontrib><creatorcontrib>Ghatei, Mohammad A</creatorcontrib><creatorcontrib>Godsland, Ian F</creatorcontrib><creatorcontrib>Bloom, Stephen R</creatorcontrib><title>Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY(3-36) and GLP-1(7-36 amide), on glucose homeostasis are unknown. This study sought to investigate the acute effects of PYY(3-36) and GLP-1(7-36) amide, individually and in combination, on insulin secretion and sensitivity. Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY(3-36) alone, GLP-1(7-36) amide alone, and a combination of PYY(3-36) and GLP-1(7-36) amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. PYY(3-36) alone caused a small but nonsignificant increase in AIRg. GLP-1(7-36) amide alone and the combination of PYY(3-36) and GLP-1(7-36) amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. PYY(3-36) lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-1(7-36) amide alone and the combination of PYY3-36 and GLP-1(7-36) amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY(3-36) and GLP-1(7-36) amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.</description><subject>Adult</subject><subject>Blood Glucose</subject><subject>Female</subject><subject>Glucagon-Like Peptide 1 - pharmacology</subject><subject>Glucose - administration &amp; dosage</subject><subject>Glucose Tolerance Test</subject><subject>Homeostasis - drug effects</subject><subject>Humans</subject><subject>Insulin - blood</subject><subject>Insulin Resistance</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity - blood</subject><subject>Overweight - blood</subject><subject>Peptide Fragments - pharmacology</subject><subject>Peptide YY - pharmacology</subject><subject>Young Adult</subject><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo1kM1LAzEQxYMgtlZvniXHekjNJNlse5SitVDQgwo9Ldlk1qbsl5tdpP-90dbTvDe_x4MZQm6Az0AAv9_bmeCgmAAlz8gYFiphKSzSEbkMYc8jUom8ICORRKWlGJPDsqlyX5veNzVtCtpi23uHdLuVTGr67fsdXW1eGUzT6O-oqX6pNUPAQE1NfW07NAGjoIXvQs_a3dGGoYy7gJH_lZuix46uP-hnOdgm4BU5L0wZ8Po0J-T96fFt-cw2L6v18mHDWlDQs4TrhXLpXFtMTWGki3dKcA743CpjbK651k5KAGUWOaDUOi8SLSTniRJOywmZHnvbrvkaMPRZ5YPFsjQ1NkPIQAvBNYBMY_T2FB3yCl3Wdr4y3SH7f5f8AfRAZ7k</recordid><startdate>201411</startdate><enddate>201411</enddate><creator>Tan, Tricia M</creator><creator>Salem, Victoria</creator><creator>Troke, Rachel C</creator><creator>Alsafi, Ali</creator><creator>Field, Benjamin C T</creator><creator>De Silva, Akila</creator><creator>Misra, Shivani</creator><creator>Baynes, Kevin C R</creator><creator>Donaldson, Mandy</creator><creator>Minnion, James</creator><creator>Ghatei, Mohammad A</creator><creator>Godsland, Ian F</creator><creator>Bloom, Stephen R</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201411</creationdate><title>Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose</title><author>Tan, Tricia M ; Salem, Victoria ; Troke, Rachel C ; Alsafi, Ali ; Field, Benjamin C T ; De Silva, Akila ; Misra, Shivani ; Baynes, Kevin C R ; Donaldson, Mandy ; Minnion, James ; Ghatei, Mohammad A ; Godsland, Ian F ; Bloom, Stephen R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-50694d786ce7afa3d21031dd108c4aacb6066d33114a9b1e366bf562300542d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Blood Glucose</topic><topic>Female</topic><topic>Glucagon-Like Peptide 1 - pharmacology</topic><topic>Glucose - administration &amp; dosage</topic><topic>Glucose Tolerance Test</topic><topic>Homeostasis - drug effects</topic><topic>Humans</topic><topic>Insulin - blood</topic><topic>Insulin Resistance</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity - blood</topic><topic>Overweight - blood</topic><topic>Peptide Fragments - pharmacology</topic><topic>Peptide YY - pharmacology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tan, Tricia M</creatorcontrib><creatorcontrib>Salem, Victoria</creatorcontrib><creatorcontrib>Troke, Rachel C</creatorcontrib><creatorcontrib>Alsafi, Ali</creatorcontrib><creatorcontrib>Field, Benjamin C T</creatorcontrib><creatorcontrib>De Silva, Akila</creatorcontrib><creatorcontrib>Misra, Shivani</creatorcontrib><creatorcontrib>Baynes, Kevin C R</creatorcontrib><creatorcontrib>Donaldson, Mandy</creatorcontrib><creatorcontrib>Minnion, James</creatorcontrib><creatorcontrib>Ghatei, Mohammad A</creatorcontrib><creatorcontrib>Godsland, Ian F</creatorcontrib><creatorcontrib>Bloom, Stephen R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tan, Tricia M</au><au>Salem, Victoria</au><au>Troke, Rachel C</au><au>Alsafi, Ali</au><au>Field, Benjamin C T</au><au>De Silva, Akila</au><au>Misra, Shivani</au><au>Baynes, Kevin C R</au><au>Donaldson, Mandy</au><au>Minnion, James</au><au>Ghatei, Mohammad A</au><au>Godsland, Ian F</au><au>Bloom, Stephen R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2014-11</date><risdate>2014</risdate><volume>99</volume><issue>11</issue><spage>E2317</spage><epage>E2324</epage><pages>E2317-E2324</pages><eissn>1945-7197</eissn><abstract>The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY(3-36) and GLP-1(7-36 amide), on glucose homeostasis are unknown. This study sought to investigate the acute effects of PYY(3-36) and GLP-1(7-36) amide, individually and in combination, on insulin secretion and sensitivity. Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY(3-36) alone, GLP-1(7-36) amide alone, and a combination of PYY(3-36) and GLP-1(7-36) amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. PYY(3-36) alone caused a small but nonsignificant increase in AIRg. GLP-1(7-36) amide alone and the combination of PYY(3-36) and GLP-1(7-36) amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. PYY(3-36) lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-1(7-36) amide alone and the combination of PYY3-36 and GLP-1(7-36) amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY(3-36) and GLP-1(7-36) amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.</abstract><cop>United States</cop><pmid>25144632</pmid><doi>10.1210/jc.2014-2143</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1945-7197
ispartof The journal of clinical endocrinology and metabolism, 2014-11, Vol.99 (11), p.E2317-E2324
issn 1945-7197
language eng
recordid cdi_proquest_miscellaneous_1622061137
source Oxford Journals Online
subjects Adult
Blood Glucose
Female
Glucagon-Like Peptide 1 - pharmacology
Glucose - administration & dosage
Glucose Tolerance Test
Homeostasis - drug effects
Humans
Insulin - blood
Insulin Resistance
Male
Middle Aged
Obesity - blood
Overweight - blood
Peptide Fragments - pharmacology
Peptide YY - pharmacology
Young Adult
title Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A36%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20peptide%20YY3-36%20with%20GLP-1(7-36)%20amide%20causes%20an%20increase%20in%20first-phase%20insulin%20secretion%20after%20IV%20glucose&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Tan,%20Tricia%20M&rft.date=2014-11&rft.volume=99&rft.issue=11&rft.spage=E2317&rft.epage=E2324&rft.pages=E2317-E2324&rft.eissn=1945-7197&rft_id=info:doi/10.1210/jc.2014-2143&rft_dat=%3Cproquest_pubme%3E1622061137%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p141t-50694d786ce7afa3d21031dd108c4aacb6066d33114a9b1e366bf562300542d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1622061137&rft_id=info:pmid/25144632&rfr_iscdi=true